CURX
Curanex Pharmaceuticals Inc Common Stock
NASDAQ · Healthcare · Biotechnology · US
$5.16
+8.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 26.0K |
| Cost of Revenue | 69.3K | — | — | — | 21.6K |
| Gross Profit | (69.3K) | — | — | — | 4.4K |
| Operating Expenses | |||||
| R&D Expense | 7.8M | 3.0M | — | — | — |
| SG&A Expense | 2.7M | 1.3M | 290.4K | 19.3K | 24.7K |
| General & Admin Expense | 1.9M | 1.3M | 290.4K | 19.3K | 24.7K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (35.0K) | — | 74.7K | — | — |
| Total Operating Expenses | 10.5M | 4.2M | 365.1K | 19.3K | 24.7K |
| Cost and Expenses | 10.6M | 4.2M | 365.1K | 19.3K | 46.2K |
| Operating Income (EBIT) | (10.6M) | (4.2M) | (365.1K) | (19.3K) | (20.2K) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 4.1K | 8.5K | — | — | — |
| Net Interest Income | (4.1K) | (8.5K) | — | — | — |
| Other Non-Op Income/Expense | 84.5K | 14.0K | 3.6K | 100.00 | — |
| Non-Operating Income (excl Interest) | (35.9K) | (22.5K) | (74.7K) | — | — |
| EBT (Pre-Tax Income) | (10.5M) | (4.2M) | (361.5K) | (19.2K) | (20.2K) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.5M) | (4.2M) | (361.5K) | (19.2K) | (20.2K) |
| Earnings from Cont. Ops | (10.5M) | (4.2M) | (361.5K) | (19.2K) | (20.2K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.5M) | (4.2M) | (361.5K) | (19.2K) | (20.2K) |
| Per Share | |||||
| Basic EPS | ($7.38) | ($2.98) | ($0.26) | ($0.01) | ($0.01) |
| Diluted EPS | ($7.38) | ($2.98) | ($0.26) | ($0.01) | ($0.01) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M |
| Diluted Shares Outstanding | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M |
| Profitability Metrics | |||||
| EBITDA | (10.4M) | (4.2M) | (290.4K) | (17.5K) | 925.00 |
| D&A | 84.8K | — | — | 1.8K | 21.2K |
| EBIT | (10.5M) | (4.2M) | (290.4K) | (19.3K) | (20.2K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026